边素艳,盖鲁粤

• 1: 中国人民解放军总医院心内科
• 2:中国人民解放军总医院心内科

摘要(Abstract)：

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 边素艳,盖鲁粤

参考文献(References)：

• [1]Stubbs MT,Bode W.A player of many parts:the spotlight falls on thrombin’s structure.Thromb Res,1993,69:1258.
• [2]Hirsh J,Warkentin TE,Raschke R,et al.Heparin and low-mo-lecular-weight heparin.Mechanisms of action,pharmacokinetics,dosing considerations,monitoring,and safety.Chest,1998,114(Suppl):489S-510S.
• [3]Weitz JI,Buller HR.Direct thrombin inhibitors in acute coronary syndromes:present and future.Circulation,2002,105:1004-1011.
• [4]Bates SM,Weitz JI.Direct thrombin inhibitors for treatment of arterial thrombosis:potential differences between bivalirudin and hirudin.Am J Cardiol,1998,82(Suppl):12P-18P.
• [5]Nawarskas JJ,Anderson JR.Bivalirudin:a newapproach to an-ticoagulation.Heart Dis,2001,3:131-137.
• [6]Topol EJ,Bonan R,Jewitt D,et al.Use of a direct antithrom-bin,Hirulog,in place of heparin during coronary angioplasty.Circulation,1993,87:1622-1629.
• [7]Bittl JA,Strony J,Brinker JA,et al.Treatment with bivalirudin(Hirulog)as compared with heparin during coronary angioplasty for unstable or postinfarction angina.N Engl J Med,1995,333:764-769.
• [8]Bittl JA,Chaitman BR,Feit F,et al.Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina:Final report reanalysis of the Bivalirudin Angioplasty Study.Am Heart J,2001,142:952-959.
• [9]Dangas G,Lasic Z,Mehran R,et al.Effectiveness of the con-comitant use of bivalirudin and drug-eluting stents(from the pro-spective,multicenter BivAlirudin and Drug-Eluting STents[ADEST]study).Am J Cardiol,2005,96:659-663.
• [10]Rajagopal V,Lincoff AM,Cohen DJ,et al.Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention:an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events(REPLACE-2)trial.Am Heart J,2006,152:149-154.
• [11]Popma JJ,Berger P,Ohman EM,et al.Antithrombotic therapy during percutaneous coronary intervention:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest,2004,126:576S-599S.
• [12]Sharma GVRK,Lapsley D,Vita JA,et al.Usefulness and toler-ability of Hirulog,a direct thrombin-inhibitor,in unstable angina pectoris.Am J Cardiol,1993,72:1357-1360.
• [13]Lid幃n RM,Théroux P,Juneau M,et al.Initial experience with a direct antithrombin,Hirulog,in unstable angina.Anticoagu-lant,antithrombotic,and clinical effects.Circulation,1993,88:1495-1501.
• [14]Fuchs J,Cannon CP,TIMI7Investigators.Hirulog in the treat-ment of unstable angina.Results of the Thrombin Inhibition in Myocardial Ischemia(TIMI)7trial.Circulation,1995,92:727-733.
• [15]Stone GW,Bertrand M,Colombo A,et al.Acute Catheterization and Urgent Intervention Triage strategY(ACUITY)trial:study design and rationale.Am Heart J,2004,148:764-775.
• [16]Lid幃n RM,ThérouxP,Lespérance J,et al.Apilot,early angio-graphic patency study using a direct thrombin inhibitor as adjunc-tive therapy to streptokinase in acute myocardial infarction.Cir-culation,1994,89:1567-1572.
• [17]Théroux P,Pérez-Villa F,Waters D,et al.Randomized double-blind comparison of two doses of Hirulog with heparin as adjunc-tive therapy to streptokinase to promote early patency of the in-farct-related artery in acute myocardial infarction.Circulation,1995,91:2132-2139.
• [18]White HD,Aylward PE,Frey MJ,et al.Randomized,double-blind comparison of Hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction(HE-RO).Circulation,1997,96:2155-2161.
• [19]White H.Hirulog and Early Reperfusion or Occlusion(HERO)-2Trial Investigators.Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic thera-py for acute myocardial infarction:the HERO-2randomised trial.Lancet,2001,358:1855-1863.
• [20]Mahaffey KW,Lewis BE,Wildermann NM,et al.The anticoag-ulant therapy with bivalirudin to assist in the performance of per-cutaneous coronary intervention in patients with heparin-induced thrombocytopenia(ATBAT)study:main results.J Invasive Car-diol,2003,15:611-616.
• [21]Eres A.Use of bivalirudin as the foundation anticoagulant during percutaneous peripheral interventions.J Invasive Cardiol,2006,18:125-128.
• [22]Dyke CM,Smedira NG,Koster A,et al.A comparison of bival-irudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass:the EVOLUTION-ON study.J Thorac Cardiovasc Surg,2006,131:533-539.
• [23]Chew DP,Bhatt DL,Kimball W,et al.Bivalirudin provides in-creasing benefit with decreasing renal function:a meta-analysis of randomized trials.Am J Cardiol,2003,92:919-923.